Sanofi (ENXTPA:SAN) As Value Debate Grows Following Its Latest Share Capital Update

Sanofi (ENXTPA:SAN) has updated investors on its share capital, publishing the total number of issued shares and voting rights as of 31 August 2026 in line with French regulatory requirements.

Sanofi’s share price has slipped over recent months, with the 7 day and 90 day share price returns both declining roughly 4% and 3% respectively. The year-to-date move is down 11%, yet the 5 year total shareholder return remains positive at about 11%.

Benchmark Sanofi’s recent share price slide against other large pharma players by scanning a curated set of list of solid balance sheet and fundamentals (194 results) for comparison.

Sanofi’s share price has retreated while analyst targets and intrinsic value estimates sit higher, creating a wide gap. Is that discount pointing to opportunity, or does it reflect risks that the models are not capturing?

Most Popular Narrative: 1.4% Overvalued

Sanofi’s narrative fair value of €72.23 sits just below the recent share price of €73.26, which keeps the current valuation debate finely balanced.

Der französische Pharmariese Sanofi bietet Anlegern derzeit eine interessante Kombination aus attraktiver Bewertung, starker Dividendenrendite und solider operativer Dynamik.​ Attraktive Bewertung und Kursrücksetzer: Die Aktie hat in den vergangenen Monaten nachgegeben und bewegt sich im Bereich von rund 76 bis 77 EUR. Damit notiert sie deutlich unter ihren früheren Höchstständen. Für langfristig orientierte Investoren eröffnet dieser Rücksetzer einen günstigen Einstiegspunkt, da das Kurs-Gewinn-Verhältnis (KGV) auf Basis der erwarteten Gewinne moderat ist und Analysten den fairen Wert spürbar höher ansetzen.

Read the complete narrative.

There is a specific profit margin path baked into this fair value. The narrative also leans on a distinct earnings trajectory and a defined revenue glide path. Curious which combination of those levers gets Sanofi to that price.

Result: Fair Value of €72.23 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, the Sanofi story could be challenged if key drugs face faster than expected patent pressure, or if pipeline assets encounter meaningful regulatory or trial setbacks.

Find out about the key risks to this Sanofi narrative.

Another View On Sanofi’s Value

The narrative fair value suggests Sanofi is slightly overvalued at €72.23 against a €73.26 share price. Our DCF model tells a very different story. It points to a future cash flow value of €239.05, which would place the current quote at a steep discount. Which set of assumptions do you trust more: the market mood or the cash flow math?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sanofi for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 183 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Mixed messages around Sanofi can be confusing. Move quickly to inspect the numbers, weigh the upside against the concerns, and decide where you stand with the 3 key rewards and 3 important warning signs

Looking for more investment ideas beyond Sanofi?

Use the Simply Wall Street Screener to scan fresh opportunities, compare quality, and build a wider watchlist that fits how you like to invest.

• Target resilient potential by focusing on businesses that pass strict risk checks through the 99 resilient stocks with low risk scores.
• Hunt for potential value by reviewing the 183 high quality undervalued stocks that combine strong fundamentals with prices below estimated worth.
• Lock in income ideas by checking companies in the 161 dividend fortresses that pair higher yields with robust underlying metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com